Gerard Vreugdenhil

8.2k total citations
165 papers, 5.0k citations indexed

About

Gerard Vreugdenhil is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gerard Vreugdenhil has authored 165 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Oncology, 34 papers in Hematology and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gerard Vreugdenhil's work include Cancer Treatment and Pharmacology (37 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Cancer survivorship and care (20 papers). Gerard Vreugdenhil is often cited by papers focused on Cancer Treatment and Pharmacology (37 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Cancer survivorship and care (20 papers). Gerard Vreugdenhil collaborates with scholars based in Netherlands, United States and Germany. Gerard Vreugdenhil's co-authors include Floortje Mols, Lonneke V. van de Poll‐Franse, Antoinetta J. M. Beijers, J.W.W. Coebergh, A. J. G. Swaak, H.G. van Eijk, V.E.P.P. Lemmens, Goof Schep, Adri C. Voogd and A.J.J.M. Vingerhoets and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Gerard Vreugdenhil

156 papers receiving 4.9k citations

Peers

Countries citing papers authored by Gerard Vreugdenhil

Since Specialization

Citations

This map shows the geographic impact of Gerard Vreugdenhil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerard Vreugdenhil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerard Vreugdenhil more than expected).

Fields of papers citing papers by Gerard Vreugdenhil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerard Vreugdenhil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerard Vreugdenhil. The network helps show where Gerard Vreugdenhil may publish in the future.

Co-authorship network of co-authors of Gerard Vreugdenhil

This figure shows the co-authorship network connecting the top 25 collaborators of Gerard Vreugdenhil. A scholar is included among the top collaborators of Gerard Vreugdenhil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerard Vreugdenhil. Gerard Vreugdenhil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry 2025 ·European Journal of Cancer ·Martin W. Bloem, Karijn P.M. Suijkerbuijk, (unknown), Franchette W.P.J. van den Berkmortel, (unknown), Willeke A.M. Blokx, Marye J. Boers‐Sonderen, (unknown), Jan Willem B. de Groot, (unknown), Geke A.P. Hospers, Ellen Kapiteijn, (unknown), Djura Piersma, Bart Rikhof, (unknown), (unknown), Gerard Vreugdenhil, Michel W.J.M. Wouters, (unknown)	0
2	Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score–matched recurrence-free, distant metastasis-free, and overall survival analysis. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Maureen J.B. Aarts, Franchette van den Berkmortel, Christian U. Blank, Willeke A.M. Blokx, Marye J. Boers‐Sonderen, Han J. Bonenkamp, Jan Willem de Groot, John B.A.G. Haanen, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, (unknown), (unknown), (unknown), Gerard Vreugdenhil, Alfonsus Johannes Maria van den Eertwegh, Karijn P.M. Suijkerbuijk, Michel W.J.M. Wouters	1
3	Changes in perception of prognosis in the last year of life of patients with advanced cancer and its associated factors: Longitudinal results of the eQuiPe study 2024 ·Palliative Medicine ·(unknown), Lonneke V. van de Poll‐Franse, (unknown), Hanneke W. M. van Laarhoven, Gerard Vreugdenhil, Inge Henselmans, Linda Brom, Evelien Kuip, Yvette M. van der Linden, Natasja Raijmakers	0
4	A conceptual framework for cautious escalation of anticancer treatment: How to optimize overall benefit and obviate the need for de-escalation trials 2024 ·Cancer Treatment Reviews ·(unknown), (unknown), Réza Elaidi, Dario Trapani, Florian Strasser, Gerard Vreugdenhil, Mike Clarke	0
5	TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment 2023 ·BMJ Open ·(unknown), Jean‐Paul A. van Basten, Pieter L. van den Berg, Roderick CN van den Bergh, (unknown), Joyce M. van Dodewaard-de Jong, Mathijs P. Hendriks, Sjoerd Klaver, Zarina S. Lalmahomed, (unknown), Addy C.M. van de Luijtgaarden, L.A.J. Roelofs, André N. Vis, Gerard Vreugdenhil, (unknown), (unknown), Haiko J. Bloemendal, Peter F.A. Mulders, Niven Mehra	1
6	Health-state utilities in long-term advanced melanoma survivors comparable with the general population 2023 ·Quality of Life Research ·(unknown), Lonneke V. van de Poll‐Franse, Renaud Tissier, Anne Rogiers, (unknown), (unknown), Geke A.P. Hospers, Jan Willem B. de Groot, Maureen J.B. Aarts, Ellen Kapiteijn, Djura Piersma, Gerard Vreugdenhil, (unknown), Karijn P.M. Suijkerbuijk, Bart Neyns, K.J.M. Janssen, Christian U. Blank, Valesca P. Retèl, Annelies H. Boekhout	3
7	Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands 2023 ·Journal of Immunotherapy ·Michiel C.T. van Zeijl, (unknown), Liesbeth C. de Wreede, Michel W.J.M. Wouters, Doranne L. Hilarius, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, (unknown), Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers‐Sonderen, Karijn P.M. Suijkerbuijk, John B.A.G. Haanen, Alfons J.M. van den Eertwegh	8
8	End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study 2022 ·JCO Oncology Practice ·(unknown), (unknown), Michel W.J.M. Wouters, Doranne L. Hilarius, Liesbeth C. de Wreede, John B.A.G. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, (unknown), Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers‐Sonderen, Karijn P.M. Suijkerbuijk, Alfons J.M. van den Eertwegh	3
9	Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice 2021 ·International Journal of Cancer ·Michiel C.T. van Zeijl, Alfons J.M. van den Eertwegh, Michel W.J.M. Wouters, Liesbeth C. de Wreede, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan‐Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Jacobus J. M. van der Hoeven, John B.A.G. Haanen	18
10	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response 2020 ·Cancers ·Monique K. van der Kooij, (unknown), Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, Marye J. Boers‐Sonderen, Miranda P. Dierselhuis, Jan Willem B. de Groot, Geke A.P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Michel W.J.M. Wouters, John B.A.G. Haanen, Alfonsus Johannes Maria van den Eertwegh, Esther Bastiaannet, Ellen Kapiteijn	32
11	The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients 2020 ·Journal of Cancer Survivorship ·Cynthia S. Bonhof, Lonneke V. van de Poll‐Franse, Dareczka K. Wasowicz, Laurens V. Beerepoot, Gerard Vreugdenhil, Floortje Mols	37
12	Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy 2020 ·Annals of Oncology ·Antoinetta J. M. Beijers, Cynthia S. Bonhof, Floortje Mols, (unknown), Judith de Vos‐Geelen, E Jacobs, Lonneke V. van de Poll‐Franse, Gerard Vreugdenhil	62
13	Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study 2018 ·Gynecologic Oncology ·Cynthia S. Bonhof, Floortje Mols, Martine De Vos, Johanna M.A. Pijnenborg, Dorry Boll, Gerard Vreugdenhil, Nicole P. M. Ezendam, Lonneke V. van de Poll‐Franse	37
14	The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches 2016 ·Oncotarget ·D.J.A. Lobbezoo, Wilfred Truin, Adri C. Voogd, Rudi M. H. Roumen, Gerard Vreugdenhil, M. Wouter Dercksen, Franchette van den Berkmortel, Tineke J. Smilde, A. van de Wouw, Roel van Kampen, (unknown), Natascha A. J. B. Peters, Petronella G.M. Peer, Vivianne C. G. Tjan‐Heijnen	9
15	Chemotherapie-geïnduceerde perifere neuropathie. Invloed op kwaliteit van leven 2014 ·Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank ·Alexander Scheel, (unknown), Floortje Mols, (unknown), Gerard Vreugdenhil	0
16	Clinical management of women with metastatic breast cancer: a descriptive study according to age group 2006 ·BMC Cancer ·(unknown), Lonneke V. van de Poll‐Franse, Geert‐Jan Creemers, Gerard Vreugdenhil, Maurice J.C. van der Sangen, Grard A. P. Nieuwenhuijzen, Rudi M. H. Roumen, Adri C. Voogd	109
17	CBO-richtlijn 'behandeling van het mammacarcinoom' 2002 ·Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank ·Emiel J. Rutgers, J.W.R. Nortier, M.K. Tuut, Geertjan van Tienhoven, H. Struikmans, M. Bontenbal, M.F. von Meyenfeldt, Gerard Vreugdenhil, (unknown), Bert Garssen, J.L. Peterse	38
18	[Impact of the new guidelines for adjuvant systemic treatment of breast cancer at hospital level]. 2000 ·PubMed ·(unknown), Marieke W.J. Louwman, J.W.W. Coebergh, Gerard Vreugdenhil	2
19	Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures 1999 ·Rheumatology International ·Harald Peeters, Mojca Jongen‐Lavrencic, C Bakker, Gerard Vreugdenhil, F. C. Breedveld, A. J. G. Swaak	33
20	Efficacy amd tolerance of long-term treatment with granulocyte-macrophage-colony-stimulating factor in allogeneic bone-marrow transplantation recipients 1993 ·Experimental Hematology ·Gerard Vreugdenhil, A Schattenberg, Guy A. E. Vandenbosch, Frank Preyers, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact